The world’s first vaccine against the Chikungunya virus developed by the company has been approved in the USA, the Vienna-based pharmaceutical company announced in a press release.
The single dose of the live vaccine IXCHIQ has been approved by the US Food and Drug Administration (FDA) for people aged 18 and over who are at increased risk of infection with Chikungunya.
This was an accelerated approval based on neutralizing antibody titers. The continuation of this indication depends on proof of clinical benefit in confirmatory studies, Valneva explained. The company announced pivotal Phase III data for the vaccine in March 2022, showing a zero response rate of 98.9 percent after 28 days with a single vaccination.
The zero response induced by the vaccine was sustained at a rate of 96.3 percent, even six months after vaccination. The company’s Phase III results were also published in the renowned medical journal “Lancet” in June 2023. The press release explained that Valneva will continue to investigate antibody persistence for at least five years.
Chikungunya has received increasing attention in recent years. The name means “the one who walks crookedly,” a reference to the sometimes severe joint problems associated with the disease. Infection mainly occurs through the bite of infected mosquitoes of the genera Aedes albopictus (tiger mosquito) and Aedes aegypti (yellow fever mosquito). These mosquitoes are found in many cities and regions of the subtropics and mainly bite during the day.
This post has already been read 2631 times!